Corpus overview


MeSH Disease

Coinfection (23)

Infections (10)

Disease (8)

Pneumonia (7)

Death (6)

Human Phenotype


    displaying 1 - 10 records in total 24
    records per page

    Pan-Echinocandin-Resistant Candida glabrata Bloodstream Infection MESHD Complicating COVID-19: A Fatal Case Report

    Authors: Brunella Posteraro; Riccardo Torelli; Antonietta Vella; Paolo Maria Leone; Giulia De Angelis; Elena De Carolis; Giulio Ventura; Maurizio Sanguinetti; Massimo Fantoni

    id:10.20944/preprints202008.0198.v1 Date: 2020-08-07 Source:

    Coinfections MESHD with bacteria or fungi may be a frequent complication of COVID-19, although coinfections MESHD with Candida species in COVID-19 patients remain rare. We report the 53-day clinical course of a complicated type-2 diabetes patient diagnosed with COVID-19, who developed bloodstream infections MESHD initially due to methicillin-resistant Staphylococcus aureus, secondly to multidrug-resistant Gram-negative bacteria, and lastly to a possibly fatal Candida glabrata. Development of FKS-associated pan-echinocandin resistance in the C. glabrata isolated from the patient after 13 days of caspofungin treatment aggravated the situation. The patient died of septic shock MESHD shock HP shortly before the prospect of receiving potentially effective antifungal therapy. This case emphasizes the importance of early diagnosis and monitoring for antimicrobial drug-resistant coinfections MESHD to reduce their unfavorable outcomes in COVID-19 patients.

    Persistent bacterial coinfection MESHD of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer

    Authors: Zhao Cai; Yumei Liu; XiangKe Duan; Shuhong Han; Yuao Zhu; Yingdan Zhang; Chao Zhuo; Yang Liu; Liang Yang

    doi:10.1101/2020.08.05.238998 Date: 2020-08-06 Source: bioRxiv

    This study characterized a genetically adapted Pseudomonas aeruginosa small colony variant isolated from a COVID-19 patient who suffered persistent bacterial coinfection MESHD and eventually recovered from critical illness MESHD. Specification and modification of the isolates discovered at genomic and transcriptomic levels with aligned phenotypic observations indicated that these isolates formed excessive biofilm with elevated quorum sensing systems.

    Concurrent cavitary pulmonary tuberculosisand COVID-19 pneumonia MESHD pneumonia HP with in vitro immune cell anergy:a case report.

    Authors: Maria Musso; Francesco Di Gennaro; Gina Gualano; Silvia Mosti; Carlotta Cerva; Saeid Najafi Fard; Raffaella Libertone; Virginia Di Bari; Massimo Cristofaro; Roberto Tonnarini; Delia Goletti; Fabrizio Palmieri

    doi:10.21203/ Date: 2020-08-05 Source: ResearchSquare

    Tuberculosis MESHD (TB) is top infectious disease MESHD killer caused by a single organismresponsible for 1.5 million deaths MESHD in 2018. Both COVID 19 and the pandemic responseare risking to affect control measures for TB and continuity of essential services forpeople affected by this infection MESHD in western countries and even more in developingcountries. Knowledges about concomitant pulmonary TB and COVID-19 are extremelylimited. The double burden of these two diseases MESHD can have devastating effects. Herewe describe from both the clinical and the immunological point of view a case of apatient with in vitro immune cell anergy affected by bilateral cavitary pulmonary TB andsubsequent COVID-19-associated pneumonia MESHD pneumonia HP with a worst outcome. COVID-19 can bea precipitating factor in TB respiratory failure HP and, during ongoing SARS COV 2 pandemic, clinicians must be aware of this possible coinfection MESHD in differential diagnosisof patients with active TB and new or worsening chest imaging

    HIV and Human Coronavirus Coinfections MESHD: A Historical Perspective

    Authors: Palesa Makoti; Burtram C. Fielding

    id:10.20944/preprints202008.0032.v2 Date: 2020-08-04 Source:

    Seven human coronaviruses (hCoVs) are known to infect humans. The most recent one, SARS-CoV-2, was isolated and identified in January 2020 from a patient presenting with severe respiratory illness in Wuhan, China. Even though viral coinfections MESHD have the potential to influence the resultant disease MESHD pattern in the host, very few studies have looked at the disease MESHD outcomes in patients infected with both HIV and hCoVs. Groups are now reporting that even though HIV-positive patients can be infected with hCoVs, the likelihood of developing severe CoV-related diseases MESHD in these patients is often similar to what is seen in the general population. This review aimed to summarize the current knowledge of coinfections MESHD reported for HIV and hCoVs. Moreover, based on the available data, this review aimed to theorize why HIV-positive patients do not frequently develop severe CoV-related diseases MESHD.

    Previous and active tuberculosis MESHD in COVID-19 patients increases risk of death MESHD and prolongs recovery

    Authors: Karla Therese L. Sy; Nel Jason Ladiao Haw; Jhanna Uy

    doi:10.1101/2020.07.22.20154575 Date: 2020-07-26 Source: medRxiv

    Background: There is a growing literature on the association of SARS-CoV-2 and other chronic conditions, such as noncommunicable diseases MESHD. However, little is known about the impact of coinfection MESHD with tuberculosis MESHD. We aimed to compare the risk of death MESHD and recovery, as well as time-to- death MESHD and time-to-recovery TRANS, in COVID-19 patients with and without TB. Methods: We created a 4:1 propensity score matched sample of COVID-19 patients without and with tuberculosis MESHD, using COVID-19 surveillance data in the Philippines. We conducted a longitudinal cohort analysis of matched COVID-19 patients as of May 17, 2020, following them until June 15, 2020. The primary analysis estimated the risk ratios of death MESHD and recovery in patients with and without tuberculosis MESHD. Kaplan-Meier curves described time-to- death MESHD and time-to-recovery TRANS stratified by tuberculosis MESHD status, and differences in survival were assessed using the Wilcoxon test. Results: The risk of death MESHD in COVID-19 patients with tuberculosis MESHD was 2.17 times higher than in those without (95% CI: 1.40-3.37). The risk of recovery in COVID-19 patients with tuberculosis MESHD was 25% lower than in those without (RR=0.75, 95% CI 0.63-0.91). Similarly, time-to- death MESHD was significantly shorter (p=0.0031) and time-to-recovery TRANS significantly longer in patients with tuberculosis MESHD (p=0.0046). Conclusions: Our findings show that coinfection MESHD with tuberculosis MESHD increased morbidity and mortality in COVID-19 patients. Our findings highlight the need to prioritize routine and testing services for tuberculosis MESHD, although health systems are disrupted by the heavy burden of the SARS-CoV-2 pandemic.

    Weak association of coinfection MESHD by SARS-CoV-2 and other respiratory viruses with severe cases and death MESHD

    Authors: Larissa Fernandes-Matano; Irma Eloisa Monroy-Muñoz; Luis Antonio Uribe-Noguez; María de los Angeles Hernández-Cueto; Brenda Sarquiz-Martínez; Héctor Daniel Pardav&eacute-Alejandre; Andrea Santos Coy-Arechavaleta; Julio Elias Alvarado-Yaah; Teresita Rojas-Mendoza; Clara Esperanza Santacruz-Tinoco; Concepción Grajales-Muñiz; Víctor Hugo Borja-Aburto; José Esteban Muñoz-Medina

    doi:10.1101/2020.07.22.20159400 Date: 2020-07-25 Source: medRxiv

    SARS-CoV-2 is a novel coronavirus described for the first time in China in December 2019. This virus can cause a disease MESHD that ranges in spectrum from asymptomatic TRANS to severe respiratory disease MESHD with multiorgan failure, and the most severe cases are associated with some comorbidities and patient age TRANS. However, there are patients who do not have those risk factors who still develop serious disease MESHD. In this study, we identified the presence of other respiratory viruses in positive cases of COVID-19 in Mexico to determine if any coinfections MESHD were correlated with more severe manifestations of COVID-19. We analysed 103 confirmed cases TRANS of COVID-19 using RT-qPCR for the detection of 16 other respiratory viruses.Of the cases analysed, 14 (13.6%) were cases of coinfection MESHD, and 92% of them never required hospitalization, even when comorbidities and advanced age TRANS were involved. There were not significant differences between the presence of comorbidities and the mean ages of the groups TRANS. These results suggest that coinfection MESHD is not related to more severe COVID-19 and that, depending on the virus involved, it could even lead to a better prognosis. We believe that our findings may lay the groundwork for new studies aimed at determining the biological mechanism by which this phenomenon occurs and for proposing corresponding strategies to limit the progression to severe cases of COVID-19.

    Haemophilus Influenza Coinfection MESHD is Common in COVID-19 Patients

    Authors: junping yan; liangshan Hu; Seyin Zou; guochen liu; donglin cao

    doi:10.21203/ Date: 2020-07-13 Source: ResearchSquare

    Background: The combined infection MESHD rate and bacterial spectrum has not been reported in COVID-19 patients. Methods: Constant temperature amplification reaction and real-time fluorescence analysis was performed for common bacterial respiratory pathogens on sputum samples (spontaneous or induced) from a prospective cohort study of infections MESHD. Forty-nine suspected COVID-19 cases from Guangdong Second Provincial General Hospital were included in the study, 49.0% were male TRANS. Results: Probable bacterial infection MESHD was detected in 33 participants. Haemophilus influenzae was the most common bacterial pathogens detected. Conclusions: Multiple coinfections MESHD were commonly detected. Sputum multiplex PCR could become a useful diagnostic tool for bacterial respiratory infections MESHD in COVID-19 infected inpatients.

    Limited Role for Antibiotics in COVID-19: Scarce Evidence of Bacterial Coinfection MESHD

    Authors: Wenjing Wei; Jessica K Ortwine; Norman S Mang; Christopher Joseph; Brenton C Hall; Bonnie Chase Prokesch

    doi:10.1101/2020.06.16.20133181 Date: 2020-06-18 Source: medRxiv

    Background: There is currently a paucity of data describing bacterial coinfections MESHD, related antibiotic prescribing patterns, and the potential role of antimicrobial stewardship in the care of patients infected with SARS-CoV-2. Methods: This prospective, observational study was conducted from March 10, 2020 to April 21, 2020 in admitted patients with confirmed COVID-19. Patients were included if [≥] 18 years old and admitted to the hospital for further treatment. Data was collected via chart review from the enterprise electronic health record database. Data collected include factors driving antibiotic choice, indication, and duration of therapy as well as microbiological data. Findings: Antibiotics were initiated on admission in 87/147 (59%) patients. Of these, 85/87 (98%) prescriptions were empiric. The most common indication for empiric antibiotics was concern for community-acquired pneumonia MESHD pneumonia HP (76/85, 89%) with the most prescribed antibiotics being ceftriaxone and azithromycin. The median duration of antibiotic therapy was two days (interquartile range 1-5). No patients had a community-acquired bacterial respiratory coinfection MESHD, but 10/147 (7%) of patients were found to have concurrent bacterial infections MESHD from a non-respiratory source, and one patient was diagnosed with active pulmonary tuberculosis MESHD pulmonary tuberculosis HP at the time of admission for COVID-19. Interpretation: Bacterial coinfection MESHD in patients with COVID-19 was infrequent. Antibiotics are likely unnecessary in patients with mild symptoms. There is little role for broad-spectrum antibiotics to empirically treat multidrug resistant organisms in patients with COVID-19, regardless of disease MESHD severity. Antimicrobial stewardship remains important in patients infected with SARS-CoV-2.

    Genome sequencing of the first SARS-CoV-2 reported from patients with COVID-19 in Ecuador.

    Authors: Sully Marquez; Belen Prado-Vivar; Juan Jose Guadalupe; Bernardo Gutierrez Granja; Manuel Jibaja; Milton Tobar; Francisco Mora; Juan Gaviria; Maria Garcia; Edison Ligna; Franklin Espinosa; Jorge Reyes; Veronica Barragan; Patricio Rojas-Silva; Gabriel Trueba; Michelle Grunauer; Paul Cardenas

    doi:10.1101/2020.06.11.20128330 Date: 2020-06-14 Source: medRxiv

    SARS-CoV-2, the etiological agent of COVID-19 was first described in Wuhan in December 2019 and has now spread globally. Ecuador was the second country in South America to report confirmed cases TRANS. The first case reported in Quito, the capital city of Ecuador, was a tourist who came from the Netherlands and presented symptoms on March 10th, 2020 (index case). In this work we used the MinION platform (Oxford Nanopore Technologies) to sequence the metagenome of the bronchoalveolar lavage (BAL) from this case reported, and subsequently we sequenced the whole genome of the index case and other three patients using the ARTIC network protocols. Our data from the metagenomic approach confirmed the presence of SARS-CoV-2 coexisting with pathogenic bacteria suggesting coinfection MESHD. Relevant bacteria found in the BAL metagenome were Streptococcus pneumoniae MESHD pneumoniae HP, Mycobacterium tuberculosis MESHD, Staphylococcus aureus and Chlamydia spp. Lineage assignment of the four whole genomes revealed three different origins. The variant HEE-01 was imported from the Netherlands and was assigned to B lineage, HGSQ-USFQ-018, belongs to the B.1 lineage showing nine nucleotide differences with the reference strain and grouped with sequences from the United Kingdom, and HGSQ-USFQ-007 and HGSQ-USFQ-010 belong to the B lineage and grouped with sequences from Scotland. All genomes show mutations in their genomes compared to the reference strain, which could be important to understand the virulence, severity and transmissibility TRANS of the virus. Our findings also suggest that there were at least three independent introductions of SARS-CoV-2 to Ecuador.

    Clinical Characteristics and Comparative Analysis of Covid-19 Patients With or Without HIV Coinfection MESHD in Wuhan, China

    Authors: Rongrong Yang; Xien Gui; Yongxi Zhang; Yong Xiong; Shicheng Gao; Hengning Ke

    doi:10.21203/ Date: 2020-06-12 Source: ResearchSquare

    Background: COVID-19 is a public health emergency MESHD that is spreading worldwide and seriously affecting global economy. Information about the impact of HIV co- infection MESHD and anti-HIV drugs on the clinical characteristics and prognosis of COVID-19 patients remains limited.Methods: In this retrospective study, the maximum body temperatures, fever MESHD fever HP duration, chest computed tomography changes and viral shedding, lymphocyte counts changes and titer of SARS-CoV-2 antibody SERO were compared between COVID-19 patients with and without HIV infection MESHD in Zhongnan Hospital of Wuhan University from January 20th to February 14th, 2020. Results: Compared with 50 control COVID-19 patients, the two COVID-19/HIV co- infection MESHD patients had higher maximum body temperatures(40.2℃ and 40.3℃ vs 38.2℃), longer fever MESHD fever HP duration(11 days and 15 days vs 7 days), longer time of lung recovery(20 days and 24 days vs 14 days), shorter duration of viral shedding after the onset of symptoms TRANS(6 days and 4 days vs 10 days). Compared with three COVID-19 infection MESHD colleagues who had exposure history with the same COVID-19 patient, the third COVID-19/HIV co- infection MESHD patient had the same duration of viral shedding after exposure(29 days vs 29 days), lower titer of SARS-CoV-2 IgG(negative vs positive for all). Conclusion: For patients co-infected with HIV, the clinical manifestations of SARS-CoV-2 infection MESHD were diverse. The ability of those COVID-19/HIV co- infection MESHD patients with severe immunodeficiency HP to produce SARS-CoV-2 antibodies SERO were weakened. The small sample in this study implied that the effects of anti-HIV drugs in prevention and treatment of COVID-19 appears to be limited.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.